TIVORBEX®: A low-dose NSAID treatment option for patients with mild to moderate acute pain

TIVORBEX®: The lowest FDA-approved dose of indomethacin available (20 mg)

TIVORBEX is a nonsteroidal anti-inflammatory drug (NSAID) for patients with mild to moderate acute pain. Iroko Pharmaceuticals, LLC developed TIVORBEX to align with recommendations from FDA, medical organizations, and advocacy groups: Use the lowest NSAID dose possible for the shortest time needed for your treatment.

Why TIVORBEX®?

20 mg is the lowest FDA-approved dose of indomethacin available

TIVORBEX was created using SoluMatrix Fine Particle Technology™, a technology that helps drugs dissolve quickly so they can be rapidly absorbed by the body

Low-dose SoluMatrix® NSAIDs were developed by Iroko to align with recommendations from FDA, medical organizations, and advocacy groups: Use the lowest dose possible for the shortest time needed for your treatment

Do you know your NSAID dose?

Ask your doctor if you are taking the lowest dose possible for the treatment of mild to moderate acute pain. Then ask about TIVORBEX the low-dose SoluMatrix® indomethacin from Iroko.

TIVORBEX®: Clinical study results in patients with mild to moderate acute pain

In a clinical study, patients taking TIVORBEX 20 mg three times daily or 40 mg two or three times daily:

  • Had greater reductions in pain compared with patients who took placebo

TIVORBEX®: Possible side effects

Before beginning treatment with TIVORBEX, it is important to be aware of potential side effects and to discuss these potential problems with your doctor

  • The most common side effects reported in clinical studies using TIVORBEX were nausea, localized swelling or bleeding at the site of surgery, headache, dizziness, vomiting, constipation, itching, diarrhea, heartburn, light-headedness, rash, stomach pain, drowsiness, excessive sweating, decreased appetite, hot flashes, and fainting

TIVORBEX®: Dosing and administration

TIVORBEX is FDA-approved at low doses of 20 mg (3 times daily) or 40 mg (twice or 3 times daily):

  • In a clinical study, patients taking TIVORBEX had greater reductions in mild to moderate acute pain compared with patients who took placebo

TIVORBEX was developed to align with recommendations from FDA, medical organizations, and advocacy groups: Use the lowest NSAID dose possible for the shortest time needed for your treatment.

Eligible* patients
pay as little as
$10

*Terms and Conditions may apply.